Xiaona Wen

Dr. Xiaona Wen

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2023 in Chemical Reviews
Verified
Journal Article
Closed access
GCGabriel Cutshaw
Gabriel Cutshaw
SUSaji uthaman
Saji uthaman
NHNora Hassan
Nora Hassan
SKSiddhant Kothadiya
Siddhant Kothadiya
XWXiaona Wen
Xiaona Wen
RBRizia Bardhan
Rizia Bardhan

26 May 2023 in Science Immunology
Verified
Journal Article
Closed access
LWLihong Wang-Bishop
Lihong Wang-Bishop
BKBlaise Russel Kimmel
Blaise Russel Kimmel
VNVerra M. Ngwa
Verra M. Ngwa
MMMatthew Z. Madden
Matthew Z. Madden
JBJessalyn J. Baljon
Jessalyn J. Baljon
JWJohn T. Wilson
John T. Wilson
The tumor-associated vasculature imposes major structural and biochemical barriers to the infiltration of effector T cells and effective tumor control. Correlations between stimulator of interferon genes (STING) pathway activation and spontaneous T cell infiltration in human cancers led us to evaluate the effect of STING-activating nanoparticles (STANs), which are a polymersome-based platform for the delivery of a cyclic dinucleotide STING agonist, on the tumor vasculature and attendant effects on T cell infiltration and antitumor function. In multiple mouse tumor models, intravenous administration of STANs promoted vascular normalization, evidenced by improved vascular integrity, reduced tumor hypoxia, and increased endothelial cell expression of T cell adhesion molecules. STAN-mediated vascular reprogramming enhanced the infiltration, proliferation, and function of antitumor T cells and potentiated the response to immune checkpoint inhibitors and adoptive T cell therapy. We present STANs as a multimodal platform that activates and normalizes the tumor microenvironment to enhance T cell infiltration and function and augments responses to immunotherapy.

21 August 2023 in Analytical Chemistry
Verified
Journal Article
Closed access
GCGabriel Cutshaw
Gabriel Cutshaw
NHNora Hassan
Nora Hassan
SUSaji uthaman
Saji uthaman
XWXiaona Wen
Xiaona Wen
BSBhuminder Singh
Bhuminder Singh
RBRizia Bardhan
Rizia Bardhan

7 August 2023 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
LSLilly Synan
Lilly Synan
SGSaman Ghazvini
Saman Ghazvini
SUSaji uthaman
Saji uthaman
GCGabriel Cutshaw
Gabriel Cutshaw
CLChe-Yu Lee
Che-Yu Lee
RBRizia Bardhan
Rizia Bardhan

5 September 2024 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
GCGabriel Cutshaw
Gabriel Cutshaw
NJNeeraj Joshi
Neeraj Joshi
XWXiaona Wen
Xiaona Wen
EQElizabeth Quam
Elizabeth Quam
GBGalina Bogatcheva
Galina Bogatcheva
RBRizia Bardhan
Rizia Bardhan
Despite numerous screening tools for colorectal cancer (CRC), 25 % of patients are diagnosed with advanced disease. Novel diagnostic technologies that are early, accurate, and rapid are imperative to assess the therapeutic efficacy of clinical drugs and identify new biomarkers of treatment response. Here Raman spectroscopy (RS) was used to track metabolic reprogramming in KRAS‐mutant HCT116 and SW837 cells, and KRAS wild‐type CC cells. RS combined with multivariate analysis methods distinguished nonresponsive, partially responsive, and responsive cells treated with cetuximab, a monoclonal antibody for EGFR inhibition, sotorasib, a clinically approved KRAS inhibitor, and various doses of trametinib, an inhibitor of the MAPK pathway. Cells treated with a combination of subtoxic doses of trametinib and BKM120, an inhibitor of the PI3K pathway, showed a synergistic response between the two pathways. Using a supervised machine learning regression model, we established a scoring methodology trained to a priori predict therapeutic response to new treatment combinations. RS metabolites were verified with mass spectrometry, and enrichment pathways were identified, including amino acid, purine, and nicotinate and nicotinamide metabolism that differentiated monotherapy from combination therapy. Our approach may ultimately be applicable to patient‐derived primary cells and cultures of patient tumors to predict effective drugs for individualized care.

21 March 2024 in Biomaterials
Verified
Journal Article
Open access
TZTian Zhu
Tian Zhu
SASteven M. Alves
Steven M. Alves
AAArianna Adamo
Arianna Adamo
XWXiaona Wen
Xiaona Wen
KCKevin C. Corn
Kevin C. Corn
MRMarjan Rafat
Marjan Rafat
Radiation therapy (RT) is essential for triple negative breast cancer (TNBC) treatment. However, patients with TNBC continue to experience recurrence after RT. The role of the extracellular matrix (ECM) of irradiated breast tissue in tumor recurrence is still unknown. In this study, we evaluated the structure, molecular composition, and mechanical properties of irradiated murine mammary fat pads (MFPs) and developed ECM hydrogels from decellularized tissues (dECM) to assess the effects of RT-induced ECM changes on breast cancer cell behavior. Irradiated MFPs were characterized by increased ECM deposition and fiber density compared to unirradiated controls, which may provide a platform for cell invasion and proliferation. ECM component changes in collagens I, IV, and VI, and fibronectin were observed following irradiation in both MFPs and dECM hydrogels. Encapsulated TNBC cell proliferation and invasive capacity was enhanced in irradiated dECM hydrogels. In addition, TNBC cells co-cultured with macrophages in irradiated dECM hydrogels induced M2 macrophage polarization and exhibited further increases in proliferation. Our study establishes that the ECM in radiation-damaged sites promotes TNBC invasion and proliferation as well as an immunosuppressive microenvironment. This work represents an important step toward elucidating how changes in the ECM after RT contribute to breast cancer recurrence.